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SUMMARY - The study was performed to determine the consumption of imipenem and resistance
of gram-negative pathogens (Pseudomonas aeruginosa, Acinetobacter sp., Klebsiella sp., Escherichia coli,
Proteus mirabilis, Serratia marcescens, Enterobacter sp.) to imipenem. Gram-negative pathogens were
isolated at the Sestre milosrdnice University Hospital from Zagreb in 1999 and 2000. The imipenem
sensitivity testing was performed by disk diffusion and E-test methods. The consumption of imipenem
was expressed in DDD/100 hospital days in the same periods. Imipenem resistance of Acinetobacter
sp. decreased  significantly in the year 2000 (p=0.0052), especially in  the first six months (p=0.021)
when the lowest consumption of imipenem was recorded. Imipenem resistance  of other gram-nega-
tive pathogens did not decrease significantly. Results suggest that the consumption of imipenem might
lead to changes in resistance to imipenem among  Acinetobacter strains.
Key words: Gram-negative bacterial infections; Cross infections; Drug resistance; Imipenem, therapeutic
use; Imipenem, pharmacology
Introduction
The carbapenem antibiotic imipenem is a beta-lactam
antibiotic characterized by its ultrabroad spectrum of ac-
tivity against clinically important aerobic gram-positive
and gram-negative species as well as anaerobes1. Its wide
antibacterial spectrum and great beta-lactamase stability
make imipenem an option for monotherapy in serious
bacterial infections such as intra-abdominal infections,
lower respiratory infections, gynecologic infections, sep-
ticemia, genitourinary tract infections, bone and joint
infections, skin and soft tissue infections, and endocardi-
tis2,3. Its attributes make it ideally suited as first-line
empiric monotherapy for serious bacterial infections in
hospitalized patients, especially in intensive care units or
in febrile neutropenic patients, where the causative orga-
nism is unknown or resistance may be suspected4. Imipe-
nem is also a useful agent when cephalosporin-resistant
or difficult-to-treat organisms have been identified4,5.
It is often kept in reserve, and its use is commonly
restricted for fear of emergence of resistance through over-
use by clinicians. Imipenem is in clinical use for over 15
years, and development of bacterial resistance to imipe-
nem has been reported for Acinetobacter sp.6,7, Pseudomonas
aeruginosa, and Enterobacter sp.7,8 Imipenem-resistant
strains occur after increased use of imipenem6,7. Bacterial
resistance to imipenem arises from the production of
carbapenemases capable of hydrolyzing the carbapenem
nucleus, and from alteration in the porin channels in the
bacterial cell walls, thereby reducing the permeability of
the drug5,9-12. Stenotrophomonas (Xanthomonas) maltophi-
lia is intrinsically resistant to imipenem, as are  Entero-
coccus faecium and methicillin-resistant staphylococci4.
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Emergence of resistance to imipenem during treatment
has also been seen, mainly in Pseudomonas aeruginosa iso-
lated from lower respiratory tract infections13. Emergence
of quinolone-imipenem cross-resistance in Pseudomonas
aeruginosa after fluoroquinolone therapy has also been
documented14. In general, the emergence of resistance to
imipenem among gram-negative pathogens has become
an evolving, ongoing potential problem in the hospitals
that must be monitored.
The aim of the study was to determine the consump-
tion of imipenem and imipenem resistance of gram-nega-
tive pathogens.
Material and Methods
Resistance to imipenem was determined in 1999 and
2000 in the following gram-negative pathogens: Pseudo-
monas aeruginosa, Acinetobacter sp., Klebsiella sp., Escheri-
chia (E.) coli, Proteus mirabilis, Serratia marcescens and
Enterobacter sp. These microorganisms were isolated from
different clinical specimens of hospitalized patients at
Sestre milosrdnice University Hospital. Duplicate or
multiple isolates of the selected pathogens were excluded
from the study.
All microorganisms were identified according to co-
lonial morphology, Gram stain, and biochemical tests5.
Imipenem sensitivity testing was performed by the disk
diffusion method  according to the National Committee
for Clinical Laboratory Standard procedures15, and E-test
imipenem method. The consumption of imipenem was
determined in the same periods and expressed in defined
daily doses of imipenem per 100 hospital days (DDD/100
hospital days).  DDD was always 2 g of imipenem. The
consumption of imipenem for each ward was calculated
as follows: number of DDD : number of hospital days x
100. The consumption of imipenem was observed at the
following hospital wards: Department of Surgery with
intensive care unit (ICU), Department of Medicine, Divi-
son of Hematology, and Department of Pediatrics.
Results
The consumption of imipenem expressed in DDD/
100 hospital days is shown in Table 1. The highest con-
sumption of imipenem in the Hospital was recorded at the
Department of Surgery with ICU. There was an obvious
decrease in the consumption of imipenem from 1998
(1.57 DDD/100 hospital days) to 2000 (0.48 DDD/100
hospital days). The decrease in the consumption of imi-
penem was more pronounced in the first six months of
2000 than in the year 2000 as a whole. The first six months
of 2000 was the period when the consumption of imipe-
nem at Department of Surgery with ICU was lowest.
Department of Medicine showed a lower consump-
Table 1. Imipenem consumption in DDD/100 hospital days




with ICU 1.57 1.34 0.20 0.48
Department
of Medicine  0.085 0.123 0.19 0.19
Division of
Hematology • • • •
Department
of Pediatrics  0.00932  0.036 0.055 0.042
DDD/100 hospital days= defined daily doses of imipenem per 100
hospital days; ICU=intensive care unit
tion of imipenem, however, with a moderate increase from
1998 (0.085 DDD/100 hospital days) to 2000 (0.19
DDD/100 hospital days). At the Division of Hematol-
ogy of the Department of Medicine, imipenem was not
used at all.
Department of Pediatrics had a low consumption of
imipenem, however, a moderate increase from 1998
(0.00932 DDD/100 hospital days) to 2000 (0.042 DDD/
100 hospital days) was recorded.
Table 2 shows percentage of resistance to imipenem
of different gram-negative pathogens throughout the year
1999, in the first six months of 2000, and throughout the
year 2000. Imipenem resistance of Pseudomonas aeruginosa
was 13.5% in 1999, and decreased to 10.44% in 2000.
Imipenem resistance of Pseudomonas aeruginosa in the first
six months of  2000, when the consumption of imipenem
at Department of Surgery with ICU was lowest, decreased
to 8.8%.
Imipenem resistance of Acinetobacter sp. was 12.6% in
1999, decreased to 4.9% in 2000, and even to 3.6% in the
first six months of 2000, when the consumption of imi-
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penem at Department of Surgery with ICU was lowest.
Almost all resistant Acinetobacter and Pseudomonas strains
were isolated at Department of Surgery with ICU.
E. coli, Klebsiella sp., and Proteus mirabilis were the
species for which no imipenem resistance was recorded.
Imipenem resistance of Serratia marcescens was 2.7% in
Table 2. Resistance of gram-negative pathogens to imipenem
     1999  Jan-Jun 2000  Jan - Dec 2000
n  % n % p   n   %   p
Pseudomonas
aeruginosa 406 13.5 170 8.8   NS  412 10.44     NS
Acinetobacter sp. 191 12.6   84 3.6 p=0.021  224  4.9 p=0.0052
Klebsiella sp. 439   0 154   0    •  325    0      •
Escherichia coli 1101   0 515   0    • 1100    0      •
Proteus mirabilis 329   0 162   0    • 303    0      •
Serratia marcescens   37   2.7    8   0   NS   38 2.63     NS
Enterobacter sp.   28   0  12   0   NS   72 1.39     NS
%=percent of resistance to imipenem; n=number of strains tested for imipenem resistance; NS=non-sig-
nificant
1999 and 2000. Imipenem resistance of Enterobacter sp.
was 1.39% in 2000.
The test of difference between proportions was per-
formed, and level of significance was calculated (Table 2).
Significant differences (with alpha level of 0.05) were only
found for Acinetobacter sp., for both study periods.
Discussion
In recent years, several reports have emphasized the
development of resistance to imipenem among gram-
negative pathogens, especially Pseudomonas aeruginosa,
Acinetobacter sp., and Enterobacter sp. Gaynes et al., in a
study of resistance to imipenem among selected gram-
negative bacilli in the United States, found 11.1% of 3316
Pseudomonas aeruginosa tested to be resistant to imipenem,
especially those isolated from respiratory tract. Imipenem
resistance among Enterobacter sp. was 1.3%8. In a surveil-
lance study of the incidence of multi-resistance in gram-
negative bacterial isolates from ICUs in Belgium, Verbist
found 15% of Pseudomonas aeruginosa, 7% of Acinetobacter
sp., 3% of Enterobacter sp., 2% of E. coli and 3% of Kleb-
siella sp. to be resistant to imipenem16. In a study of the
prevalence of antibiotic resistance among gram-negative
bacteria in ICUs, Elhag et al. found 2% of Pseudomonas
aeruginosa, and none of E. coli and Klebsiella sp. to be re-
sistant to imipenem17. Our data on imipenem resistance
of different gram-negative pathogens are mostly consis-
tent with literature reports. In our study, a high rate of
imipenem resistance was recorded in 1999 for Acineto-
bacter sp. (12.6%) and Pseudomonas aeruginosa strains
(13.5%). Imipenem resistance of Acinetobacter sp. decrea-
sed significantly in the year 2000 (p=0.0052), especially
in the first six months (p=0.021), when the lowest con-
sumption of imipenem was recorded at the Department
of Surgery with ICU. Imipenem resistance of Pseudomo-
nas aeruginosa did not decrease significantly in 2000, al-
though a decreasing trend was observed. The significant
decrease in imipenem resistance of Acinetobacter sp. in the
period characterized by the lowest consumption of imi-
penem at the Department of Surgery with ICU suggests
that imipenem usage might lead to changes in imipenem
resistance among Acinetobacter strains.
The emergence of resistance to carbapenems of Aci-
netobacter sp. and Pseudomonas aeruginosa poses a serious
concern. The prolonged use of carbapenems in the treat-
ment of nosocomial infections can favor the development
of resistance to these antimicrobial agents. Urban et al.
report on an outbreak of infections due to Acinetobacter
baumannii resistant to carbapenems, which occurred  af-
ter an increased use of imipenem7. The spread of these
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strains within the hospital environment is a serious prob-
lem that could contribute to poor patient outcome.
Heavy and widespread use of antibiotics in hospital
does not only force the emergence of antibiotic resistance,
but also promotes selection of drug-resistant organisms in
the hospital environment. In case of imipenem, these are:
Stenotrophomonas maltophilia, imipenem resistant strains
of Acinetobacter sp., Pseudomonas aeruginosa, Serratia sp.,
Enterobacter sp., and methicillin resistant staphylococci.
Overuse of imipenem appears to continue, not without a
risk. The development of imipenem resistance during the
treatment of Pseudomonas infections has been reported13.
Imipenem has the highest induction potential of class 1
chromosomal beta-lactamases, leading to high resistance
to cephalosporins and penicillins18.  Overuse of fluoroqui-
nolones has also been associated with the development of
resistance to imipenem in Pseudomonas aeruginosa. Cross-
-resistance of ciprofloxacin and imipenem has been repor-
ted to occur after the treatment with fluoroquinolones14,19.
In conclusion, imipenem should be kept in reserve, and
its use should be controlled. Controlled use together with
an effective infection control program to prevent horizon-
tal transfer of imipenem resistant bacteria will provide a
relatively resistance-free future. An imipenem resistance
surveillance program with registration of its consumption
is necessary to promote an optimal use of imipenem and
to encourage its rational prescribing.
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Sa¾etak
POTRO'NJA IMIPENEMA I OTPORNOST GRAM NEGATIVNIH UZRO¨NIKA NA
IMIPENEM U KLINI¨KOJ BOLNICI ÒSESTRE MILOSRDNICEÓ
I. BenŁiæ, I. BenŁiæ i D. VukiŁeviæ-Baudoin
Cilj istra¾ivanja bio je odrediti potro„nju imipenema, kao i otpornost gram negativnih uzroŁnika (Pseudomonas aeruginosa,
Acinetobacter sp., Klebsiella sp., E. coli, Proteus mirabilis, Serratia marcescens, Enterobacter sp.) na imipenem. Gram negativni
uzroŁnici izolirani su u KliniŁkoj bolnici ÒSestre milosrdniceÓ 1999. i 2000. godine. Testiranje osjetljivosti na imipenem
provedeno je metodom disk difuzije i E-testom. Potro„nja imipenema je izra¾ena u DDD/100 bolniŁkih dana u istim vremenskim
razdobljima. Otpornost na imipenem u Acinetobacter sp. je statistiŁki znaŁajno pala 2000. godine (p=0,0052), a poglavito u
prvih „est mjeseci (p=0,021) kada je potro„nja imipenema bila najni¾a. Otpornost ostalih gram negativnih uzroŁnika na
imipenem nije statistiŁki znaŁajno pala. Rezultati ukazuju na to da bi potro„nja imipenema mogla utjecati na promjene u
otpornosti Acinetobacter sp. na imipenem.
KljuŁne rijeŁi: Gram-negativne bakterijske infekcije; Kri¾ne infekcije; Otpornost na lijekove; Imipenem, terapijska primjena;
Imipenem, farmakologija
